Analysts’ Viewpoint
Rise in prevalence of SCLC and the development of new and effective treatment options are expected to boost small cell lung cancer (SCLC) therapeutics market value during the forecast period. Additionally, increase in awareness about the disease, rise in availability of advanced diagnostic tools, and well-established healthcare infrastructure are some of the factors fueling market progress.
Key players operating in the small cell lung cancer therapeutics market are focusing on the development of innovative therapies and expansion of their product portfolio to gain a competitive edge. Moreover, companies are involved in strategic collaborations and partnerships to strengthen their market position. However, high cost of treatment and the lack of reimbursement policies in some regions are likely to hamper market dynamics in the next few years.
Small cell lung cancer (SCLC) is a type of lung cancer that is characterized by the rapid growth of small cells in the lung tissue. It is a highly aggressive form of cancer that is often diagnosed at an advanced stage, making it difficult to treat.
There are several types of small cell lung cancer therapeutics available in the market, including chemotherapy, radiation therapy, immunotherapy, and targeted therapy.
Chemotherapy is the most commonly used treatment for SCLC and involves the usage of drugs to kill cancer cells. Radiation therapy uses high-energy radiation to kill cancer cells and is often used in combination with chemotherapy.
Immunotherapy is a type of treatment that uses a person’s immune system to fight with cancer cells. Targeted therapy for small cell lung cancer is a type of treatment that targets specific genes or proteins or genes responsible for the growth of cancer cells.
Small cell lung cancer (SCLC) is an aggressive form of cancer that spreads rapidly and can be difficult to treat. The incidence rate of SCLC has been increasing globally, which is expected to drive the SCLC therapeutics market in the near future.
A major factor contributing to the rise in prevalence of SCLC is smoking. Smoking is a well-known risk factor for developing lung cancer, including SCLC. According to the World Health Organization (WHO), tobacco use causes approximately 70% of all cases of lung cancer worldwide. Therefore, rise in smoking rate in various parts of the world is expected to boost the incidence of SCLC during the forecast period.
Exposure to environmental toxins, such as radon and asbestos, is another factor contributing to the increase in prevalence of SCLC. Radon is a naturally occurring gas that can accumulate in buildings and homes, while asbestos was commonly used in construction materials until its health risks were discovered. Both radon and asbestos have been linked to an increased risk of developing lung cancer, including SCLC.
The treatment landscape for small cell lung cancer has been evolving significantly for the last few years with advancements in therapeutics. Emergence of targeted therapies and immunotherapies for SCLC is creating growth opportunities for market players.
Traditionally, chemotherapy has been considered a one-size-fits-all approach for cancer treatments. However, researchers currently are focusing on identification of specific biomarkers or genetic mutations associated with small-cell-lung-cancer tumors. Targeted therapy options, such as PARP inhibitors or immune checkpoint inhibitors, help benefit patients with SCLC.
PARP inhibitors are a class of drugs that target the DNA repair pathway in cancer cells. They have shown promising results in clinical trials for small cell lung cancer patients with specific genetic mutations, such as BRCA1/2.
Immune checkpoint inhibitors are another type of targeted therapy that works by blocking proteins in immune cells, which prevents them from attacking cancer cells. These therapies have been approved for use in small cell lung cancer patients who have failed to respond to traditional chemotherapy.
In terms of therapy type, chemotherapy is likely to contribute the highest share of the market during the forecast period. Chemotherapy has been a standard treatment for SCLC for several years. The primary reason behind its dominance in the market is its effectiveness in treating SCLC patients. It works by targeting rapidly dividing cancer cells and preventing them from growing further. This therapy type can be used alone or in combination with other treatments such as small cell lung cancer radiation therapy.
Another factor driving the chemotherapy segment is its affordability as compared to other therapies such as targeted therapy and immunotherapy. While targeted therapy and immunotherapy are relatively new treatments that require extensive research and development, chemotherapy drugs have been available for decades, making them more accessible to patients at lower costs.
Moreover, advancements in technology have led to improved drug delivery methods that enhance chemotherapy's efficacy while reducing its side-effects. For instance, liposomal formulations allow higher doses of chemotherapy drugs to be delivered directly into tumor cells while minimizing damage to healthy tissues surrounding them.
Additionally, ongoing clinical trials are exploring new combinations of chemotherapy drugs with other therapies that could improve patient outcomes. For instance, a study published by Bristol Myers Squibb (BMS) showed promising results when combining their immune checkpoint inhibitor Opdivo (nivolumab) with two chemotherapeutic agents - etoposide and cisplatin - as first-line treatment for advanced SCLC patients.
As per the latest small cell lung cancer (SCLC) therapeutics market forecast, in terms of drug type, the etoposide drug type segment is projected to lead the global industry during the forecast period, owing to its effectiveness in treating SCLC.
Etoposide is a chemotherapy drug that works by inhibiting topoisomerase II enzyme and preventing DNA replication in cancer cells. It is commonly used in combination with other drugs, such as cisplatin, for first-line treatment of SCLC. The drug has shown promising results in clinical trials and has been approved by regulatory authorities for use in various countries.
Studies have shown that etoposide-based chemotherapy regimens can achieve response rates ranging from 60% to 80% among patients with limited-stage or extensive-stage SCLC. This makes it one of the most effective treatments available for this type of cancer.
Another factor contributing to etoposide's popularity is its relatively low cost as compared to newer immunotherapy drugs such as pembrolizumab and atezolizumab.
The parenteral route of administration segment is anticipated to account for major small cell lung cancer (SCLC) therapeutics market share during the forecast period, owing to its ability to deliver drugs directly into the bloodstream and achieve rapid onset of action.
Parenteral administration method bypasses absorption barriers in the gastrointestinal tract and allows for more precise dosing control.
Chemotherapy agents used for SCLC usually have poor oral bioavailability or are too toxic when taken orally. For instance, etoposide has low oral bioavailability due to extensive first-pass metabolism by liver enzymes. Therefore, it must be administered intravenously or intramuscularly.
Moreover, parenteral administration allows for continuous infusion over an extended period, which may improve drug efficacy while minimizing toxicity. This approach has been shown to be effective with some chemotherapeutic agents, such as topotecan, which has demonstrated improved response rates when administered as a continuous infusion rather than a bolus injection.
North America is estimated to dominate the global market during the forecast period, owing to the high prevalence of smoking and exposure to carcinogens in the region. According to the American Cancer Society, SCLC accounts for approximately 10% to 15% of all lung cancers in the U.S. Additionally, favorable government initiatives such as funding for R&D activities are driving small cell lung cancer (SCLC) therapeutics market growth in North America.
Asia Pacific is expected to be the fastest-growing region of the global SCLC therapeutics market due to an increase in tobacco consumption and air pollution levels in the region. China has one of the highest rates of lung cancer globally, with over 700,000 new cases reported annually. Furthermore, increase in healthcare expenditure and rise in awareness about early diagnosis and treatment options are fueling small cell lung cancer (SCLC) therapeutics industry growth in this region. The lucrative presence of key players in the region is also contributing to the small cell lung cancer (SCLC) therapeutics market development in Asia Pacific.
The small cell lung cancer therapeutics market report includes vital information about the key companies operating in the industry. Companies are implementing various innovative strategies including new product launches, mergers, acquisitions, and partnerships to strengthen their position in the market.
AstraZeneca plc, Dr. Reddy's Laboratories, Inc., F. Hoffmann La-Roche Ltd., GSK plc, Jazz Pharmaceuticals plc, Merck & Co., Inc., Novartis AG, and Pfizer Inc. are the prominent players operating in the global small cell lung cancer (SCLC) therapeutics market.
Key players in the global small cell lung cancer (SCLC) therapeutics market research report have been profiled based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2022 |
US$ 4.6 Bn |
|
Market Forecast Value in 2031 |
More than US$ 12.9 Bn |
|
Compound Annual Growth Rate (CAGR) |
11.9% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes key segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 4.6 Bn in 2022
It is projected to reach more than US$ 12.9 Bn by 2031
The business is anticipated to advance at a CAGR of 11.9% from 2023 to 2031
Increase in incidence of small cell lung cancer (SCLC) and advancements in diagnosis and screening
The chemotherapy therapy type segment accounted for major share in 2022
North America is expected to showcase high demand for SCLC therapeutics during the forecast period
AstraZeneca plc, Dr. Reddy's Laboratories, Inc., F. Hoffmann-La Roche Ltd., GSK plc, Jazz Pharmaceuticals plc, Merck & Co., Inc., Novartis AG, and Pfizer Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Small Cell Lung Cancer (SCLC) Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Therapy Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, 2017 - 2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Key Industry Events
5.4. COVID-19 Impact on Industry
6. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy Type, 2017 - 2031
6.3.1. Targeted Therapy
6.3.2. Immunotherapy
6.3.3. Chemotherapy
6.4. Market Attractiveness, by Therapy Type
7. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Drug Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Type, 2017 - 2031
7.3.1. Atezolizumab
7.3.2. Durvalumab
7.3.3. Lurbinectedin
7.3.4. Pembrolizumab
7.3.5. Etoposide
7.3.6. Methotrexate
7.3.7. Topotecan
7.3.8. Others
7.4. Market Attractiveness, by Drug Type
8. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017 - 2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness, by Route of Administration
9. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2017 - 2031
11.2.1. Targeted Therapy
11.2.2. Immunotherapy
11.2.3. Chemotherapy
11.3. Market Value Forecast, by Drug Type, 2017 - 2031
11.3.1. Atezolizumab
11.3.2. Durvalumab
11.3.3. Lurbinectedin
11.3.4. Pembrolizumab
11.3.5. Etoposide
11.3.6. Methotrexate
11.3.7. Topotecan
11.3.8. Others
11.4. Market Value Forecast, by Route of Administration, 2017 - 2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017 - 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Therapy Type
11.7.2. By Drug Type
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017 - 2031
12.2.1. Targeted Therapy
12.2.2. Immunotherapy
12.2.3. Chemotherapy
12.3. Market Value Forecast, by Drug Type, 2017 - 2031
12.3.1. Atezolizumab
12.3.2. Durvalumab
12.3.3. Lurbinectedin
12.3.4. Pembrolizumab
12.3.5. Etoposide
12.3.6. Methotrexate
12.3.7. Topotecan
12.3.8. Others
12.4. Market Value Forecast, by Route of Administration, 2017 - 2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country, 2017 - 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Therapy Type
12.7.2. By Drug Type
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country
13. Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017 - 2031
13.2.1. Targeted Therapy
13.2.2. Immunotherapy
13.2.3. Chemotherapy
13.3. Market Value Forecast, by Drug Type, 2017 - 2031
13.3.1. Atezolizumab
13.3.2. Durvalumab
13.3.3. Lurbinectedin
13.3.4. Pembrolizumab
13.3.5. Etoposide
13.3.6. Methotrexate
13.3.7. Topotecan
13.3.8. Others
13.4. Market Value Forecast, by Route of Administration, 2017 - 2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country, 2017 - 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Therapy Type
13.7.2. By Drug Type
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country
14. Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017 - 2031
14.2.1. Targeted Therapy
14.2.2. Immunotherapy
14.2.3. Chemotherapy
14.3. Market Value Forecast, by Drug Type, 2017 - 2031
14.3.1. Atezolizumab
14.3.2. Durvalumab
14.3.3. Lurbinectedin
14.3.4. Pembrolizumab
14.3.5. Etoposide
14.3.6. Methotrexate
14.3.7. Topotecan
14.3.8. Others
14.4. Market Value Forecast, by Route of Administration, 2017 - 2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country, 2017 - 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Therapy Type
14.7.2. By Drug Type
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country
15. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapy Type, 2017 - 2031
15.2.1. Targeted Therapy
15.2.2. Immunotherapy
15.2.3. Chemotherapy
15.3. Market Value Forecast, by Drug Type, 2017 - 2031
15.3.1. Atezolizumab
15.3.2. Durvalumab
15.3.3. Lurbinectedin
15.3.4. Pembrolizumab
15.3.5. Etoposide
15.3.6. Methotrexate
15.3.7. Topotecan
15.3.8. Others
15.4. Market Value Forecast, by Route of Administration, 2017 - 2031
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country, 2017 - 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Therapy Type
15.7.2. By Drug Type
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2021)
16.3. Company Profiles
16.3.1. AstraZeneca plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Test Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Dr. Reddy's Laboratories, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Test Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann La-Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Test Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. GSK plc
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Test Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Jazz Pharmaceuticals plc
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Test Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck & Co., Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Test Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Test Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Pfizer Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Test Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
List of Tables
Table 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 02: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 03: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 05: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 08: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 09: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 10: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 11: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 12: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 13: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 14: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 15: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 18: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 19: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 20: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 22: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 23: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 24: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 25: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 26: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 27: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 28: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 29: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 30: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Therapy Type, 2022
Figure 03: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Drug Type, 2022
Figure 04: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Route of Administration, 2022
Figure 05: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Distribution Channel, 2022
Figure 06: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 07: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 08: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Targeted Therapy, 2017-2031
Figure 09: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Immunotherapy, 2017-2031
Figure 10: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Chemotherapy, 2017-2031
Figure 11: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 12: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 13: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Atezolizumab, 2017-2031
Figure 14: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Durvalumab, 2017-2031
Figure 15: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Lurbinectedin, 2017-2031
Figure 16: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Pembrolizumab, 2017-2031
Figure 17: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Etoposide, 2017-2031
Figure 18: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Methotrexate, 2017-2031
Figure 19: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Topotecan, 2017-2031
Figure 20: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Others, 2017-2031
Figure 21: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 22: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 23: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Oral, 2017-2031
Figure 24: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Parenteral, 2017-2031
Figure 25: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Others, 2017-2031
Figure 26: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 27: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 28: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 29: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 30: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Online Pharmacies, 2017-2031
Figure 31: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
Figure 32: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
Figure 33: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 34: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 35: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 36: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 37: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 38: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 39: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 40: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 41: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 42: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 43: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 44: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 45: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 46: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 47: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 48: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 49: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 50: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 51: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 52: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 53: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 54: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 55: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 56: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 57: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 58: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 59: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 60: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 61: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 62: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 63: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 64: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 65: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 65: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 67: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 68: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 69: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 70: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 71: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 71: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 73: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 74: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 75: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 76: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 77: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 78: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 79: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 80: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 81: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 82: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 83: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 84: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 85: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 86: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 87: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 88: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Small Cell Lung Cancer (SCLC) Therapeutics Market
